Your Followed Topics

Top 2 astrazeneca News Today

#1
Key facts: AstraZeneca acquires Modella AI; plans $50B U.S. investment
#1 out of 2
business1d ago

Key facts: AstraZeneca acquires Modella AI; plans $50B U.S. investment

https://www.tradingview.com/news/tradingview:a1853a915e6b6:0-key-facts-astrazeneca-acquires-modella-ai-plans-50b-u-s-investment/
Tradingview.com
  • AstraZeneca will acquire Modella AI to boost oncology drug research with AI capabilities.
  • The financial terms were not disclosed as part of the announced deal.
  • AstraZeneca aims for about $80 billion in annual revenue by 2030.
  • The company plans to invest $50 billion in U.S. manufacturing by 2030.
  • The U.S. investment includes a major facility in Virginia and additional state expansions.
  • AstraZeneca is also managing inventory impacts related to tariffs as part of its strategy.
  • The announcements reflect a broader push to integrate AI into drug discovery and expand U.S. production.
  • The deal underscores AstraZeneca’s strategy to leverage AI in oncology research.
  • The source highlights the acquisition as part of a broader U.S. investment plan through 2030.
  • The article notes the U.S. investment as a key component of the broader corporate strategy.
Vote 0
0
#2
JPM26 Day 2: Companies Lay Out Near-Term Revenue, Longer-Term Business Goals
#2 out of 2562.0 est. views
business17h ago

JPM26 Day 2: Companies Lay Out Near-Term Revenue, Longer-Term Business Goals

https://www.biospace.com/business/jpm26-day-2-companies-lay-out-near-term-revenue-longer-term-business-goals
Biospace.com
  • AstraZeneca reiterates an $80B revenue goal for 2030 and outlines near-term launches to support it.
  • BioNTech shifts focus from COVID to cancer, prioritizing late-stage readouts and pumitamig programs.
  • AbbVie acquires ex-China rights to a PD-1/VEGF bispecific from RemeGen, signaling aggressive positioning in bispecifics.
  • Agios projects a $10B market by 2030, expanding beyond ultra-rare diseases into broader portfolios.
  • Acadia aims for $1B Nuplazid and $700M Daybue sales by 2028, signaling aggressive growth expectations.
  • Policy moves at JPM26 show Acadia CEO lobbying against MFN pricing for small biotechs.
  • Company reports highlight a broader trend of near-term launches underpinning long-term revenue plans.
  • BioNTech’s pumitamig could become a next-generation IO backbone if readouts are favorable.
  • BMO analysts see eight pivotal studies across oncology signaling significant execution risk and potential upside for BioNTech.
  • The JPM26 event underscored how near-term product launches align with longer-term pipeline value.
Vote 0
0

Explore Your Interests

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement